(Q40957027)

25 September 2017

1 reference

title

Topoisomerase I interactive drugs in children with cancer (English)

1 reference

25 September 2017

C F Stewart

1

1 reference

25 September 2017

W C Zamboni

2

1 reference

25 September 2017

W R Crom

3

1 reference

25 September 2017

A Gajjar

4

1 reference

25 September 2017

R L Heideman

5

1 reference

25 September 2017

W L Furman

6

1 reference

25 September 2017

W H Meyer

7

1 reference

25 September 2017

P J Houghton

8

1 reference

25 September 2017

C B Pratt

9

1 reference

25 September 2017

publication date

1 January 1996

1 reference

Investigational New Drugs

25 September 2017

published in

1 reference

25 September 2017

volume

14

1 reference

25 September 2017

issue

1

1 reference

25 September 2017

page(s)

37-47

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00173681

25 September 2017

exact match

0 references

cites work

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1 reference

12 December 2020

Multilevel therapeutic targeting by topoisomerase inhibitors

1 reference

12 December 2020

Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts

1 reference

12 December 2020

Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.

1 reference

12 December 2020

Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture

1 reference

12 December 2020

Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs

1 reference

12 December 2020

Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates

1 reference

12 December 2020

High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma

1 reference

12 December 2020

Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

1 reference

12 December 2020

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

12 December 2020

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhi

1 reference

12 December 2020

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

1 reference

12 December 2020

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

1 reference

12 December 2020

Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma

1 reference

12 December 2020

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1 reference

12 December 2020

Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy

1 reference

12 December 2020

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

1 reference

12 December 2020

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea

1 reference

12 December 2020

Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.

1 reference

12 December 2020

The current status of camptothecin analogues as antitumor agents

1 reference

12 December 2020

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity

1 reference

12 December 2020

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

12 December 2020

Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors

1 reference

12 December 2020

Intrathecal administration of topotecan in nonhuman primates

1 reference

12 December 2020

Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy

1 reference

12 December 2020

Phase I study of topotecan for pediatric patients with malignant solid tumors

1 reference

12 December 2020

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

12 December 2020

Topoisomerase I inhibitors. An overview of the camptothecin analogs.

1 reference

12 December 2020

Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion

1 reference

12 December 2020

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

1 reference

12 December 2020

DNA topoisomerases: essential enzymes and lethal targets

1 reference

12 December 2020

Antineoplastic Agents from Plants

1 reference

12 December 2020

Eukaryotic DNA topoisomerases I.

1 reference

12 December 2020

Camptothecins: from bench research to hospital wards.

1 reference

12 December 2020

In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00173681

1 reference

Dimensions Publication ID

25 September 2017

1043110765

0 references

Fatcat ID

release_qnl3fo2tqrbhljrew5ziv4lt5i

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qnl3fo2tqrbhljrew5ziv4lt5i

24 November 2022

mapped directly with Wikidata item

1 reference